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Summary The aim of this study was to investigate whether immunohistochemical staining patterns of tissue inhibitor of metalloproteinases
TIMP-2 and matrix metalloproteinases MMP-2 and MMP-9 can be predictors of tumour stage and survival time in colorectal cancer. Frozen
tumour sections from 212 patients operated on between January 1987 and November 1990 were investigated. Three mouse monoclonal
antibodies - T2-101 against TIMP-2, CA-4001 against MMP-2 and GE-213 against MMP-9 - were used. Positive expression of TIMP-2 (a) in
basement membranes and (b) diffusely in stroma with (c) subglandular enhancement was found significantly (P < 0.01, P < 0.05, P < 0.05)
more often in localized tumours than in tumours with regional or distant metastases. Neither pattern correlated with tumour differentiation.
Patterns (a) and (c) correlated with longer survival time (P< 0.05); (b) reached near significance (P< 0.07). When the survival analyses were
restricted to potentially cured patients, neither pattern could foretell death from cancer. Positive expression of MMP-2 in tumour epithelium
and of MMP-9 in tumour-infiltrating macrophages were both independent of tumour stage and were without correlation with survival time. A
large number of MMP-9-positive macrophages correlated (P< 0.05) with poortumour differentiation, whereas weak orabsent epithelial MMP-
2 staining reached near significance (P < 0.08). Exploration of TIMP-2 expression is valuable for the discrimination between macroscopically
localized and metastatic colorectal cancer, but it cannot predict which of the potentially cured patients are likely to have micrometastases.
MMP-2 and MMP-9 stainings are of minor value in staging and prognostic prediction.
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During local invasion and metastasis it is essential for tumour cells
to be able to induce degradation of basement membranes and
interstitial stroma (Liotta, 1984; Liotta etal, 1988; Nicolson, 1991;
de Clerck et al, 1994). This degradation is carried out by various
proteases, including the important family ofclosely related matrix
metalloproteinases (MMPs) (Liotta and Stetler-Stevenson, 1990;
Goldberg and Eisen, 1991; de Clerck et al, 1994; Furcht et al,
1994; Nigam et al, 1994; Thorgeirsson et al, 1994; Woessner,
1994; Birkedal-Hansen, 1995). The four subfamilies of MMPs -
collagenases, gelatinases, stromelysins and others -cleave most, if
not all, constituents ofthe extracellular matrix (ECM). Gelatinases
include a 72-kDa collagenase (MMP-2 or gelatinase A) and a 92-
kDa collagenase (MMP-9 or gelatinase B). Both enzymes degrade
the basement membrane collagen, type IV collagen, but have no
activity on interstitial collagens.
The type IV collagenase activity is modulated by tissue
inhibitors of metalloproteinases, of which TIMP-1 preferentially
affects MMP-9 and TIMP-2 preferentially affects MMP-2 (Liotta
and Stetler-Stevenson, 1990; Goldberg and Eisen, 1991; Stetler-
Stevenson et al, 1993; Hayakawa, 1994; Birkedal-Hansen, 1995).
The balance between MMPs and TIMPs is crucial for tissue
homeostasis and control of ECM turnover (Tryggvason et al,
1993; Newell et al, 1994). MMPs are secreted as proenzymes,
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which are activated extracellularly (Goldberg and Eisen, 1991; de
Clerck et al, 1994) - TIMPs inhibit not only active MMP enzyme
but also prevent activation of the proenzyme (Liotta and Stetler-
Stevenson, 1990; Fridman et al, 1993).
Tumours have been shown to have augmented immunohisto-
chemical localization oftype IV collagenases compared with non-
invasive epithelium (Liotta and Stetler-Stevenson, 1990). The
metastatic potential of a number of tumours has been shown to
correlate with their ability to degrade type IV collagen (Liotta,
1984; Goldberg and Eisen, 1991). This degradation is suggested to
be independent of the Dukes' stage in colorectal cancer in a paper
by Jessup (1994). A possible predictor of local tumour invasive-
ness has been suggested for the levels and localizations ofMMP-2
and TIMP-2 (Hoyhtya et al, 1994; Jessup, 1994), as tumour
progression may result from increased degradation or decreased
production of basement membrane components (Havenith et al,
1988; Jessup, 1994).
Dukes' classification system is still thebestprognostic predictor
in colorectal cancer (Lindmark et al, 1994), but it does not permit
discrimination between patients cured by surgery alone and
patients having micrometastases in the group potentially cured by
surgery (Newland et al, 1987). Only a limited number of studies
have reported on TIMP-1 and/or TIMP-2 and/or MMP-2, and/or
MMP-9 in colorectal cancer (Nakajima et al, 1990; Poulsom et al,
1992; Pyke et al, 1993; Emmert-Buck et al, 1994; Hoyhtya et al,
1994; Kossakowska et al, 1996; Nielsen et al, 1996; Swallow et al,
1996) and the possible correlation with tumour stage (van der
Stappen et al, 1990; Levy et al, 1991; Urbanski et al, 1993; Newell
et al, 1994; Liabakk et al, 1996) and survival (Liabakk et al, 1996).
805806 P Ring etal
The aim of the present study was to search for differences in the
expressions of the type IV collagenases MMP-2 and MMP-9 and
the inhibitor TIMP-2 in various Dukes' stages and their possible
prognostic impact, thus possibly enabling improved selection of
patients for additional therapy and surveillance.
MATERIALS AND METHODS
Patients
Two hundred and twelve potentially curable colorectal cancer
patients (124 colon, 88 rectum) with no preoperative indications
of tumour spread were operated on between January 1987 and
November 1990. No patient received adjuvant chemotherapy, while
30 patients with rectal cancer obtained preoperative radiotherapy of
25 Gy for 5 days (Glimelius et al, 1995). The patients were 122
women and 90 men of ages ranging from 40 to 92 years (median
age 70 years). One hundred and seventy-seven patients were poten-
tially cured with a radically excised tumour in Dukes' stages A-C
(38, 97 and 42 patients respectively). Thirty-five patients had either
non-radical surgery or distant metastases, and they were designated
Dukes' stage D. Survival was measured from the time ofresection
until follow-up at the end of 1994. Median survival time of 104
living patients was 66 months (range 50-93 months).
A
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Tumour biopsies
Full cross-tumour biopsies, collected from the 212 surgical speci-
mens, were frozen in dry-ice isopentane and stored at -70°C.
Biopsies for routine histopathology were taken from all tumours.
Immunohistochemical staining
Serial 6 jm cryosections were acetone fixed and stainedwith mono-
clonal antibodies againstthe MMP-2, MMP-9 and TIMP-2 antigens
using the avidin-biotin staining technique (ABC Elite, Vector,
Burlingame, CA, USA). CA-4001 was raised against the amino
terminus of the proenzyme of the human MMP-2 (Margulles et al,
1992); GE-213 was raised against intact human MMP-9, recog-
nizing both the latent and active forms ofthe enzyme (Nikkari et al,
1996); and T2-101 was raised against intact human TIMP-2, recog-
nizing an epitope between the amino acids 111-126 on the TIMP-2
molecule (Hoyhtya et al, 1994). The antibodies, used at concentra-
tions of 1.5, 10 and 20 jg ml-' respectively, were diluted in phos-
phate-buffered saline supplemented with 5% normal horse serum
and 1% bovine serum albumin and were then incubated with tissues
for 60 min at room temperature. Antibodies were omitted and
replaced by dilution buffer or normal mouse IgG as negative
controls. Biotinylated horse anti-mouse IgG (Vector, Burlingame,
CA, USA) was used at dilution 1:200 and was incubated for 30 min.
B
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Figure 1 Sections from colorectal cancer illustrating varied MMP-2 epithelial staining intensity. (A) Weak; (B) moderate; (C) strong; and (D) negative
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Figure 2 Sections from colorectal cancer illustrating (A) few and (B) many
MMP-9-positive tumour-infiltrating macrophages
Histopathological evaluation
Tumourstage and differentiation
Tumour differentiation was assessed according toWHO recommen-
dations (Morson and Sobin, 1976) and tumour staging according to
Dukes' classification system (Dukes and Bussey, 1958).
Immunohistochemistry
The sections were scanned at low magnification (x40) using light
microscopy. Areas with the predominant staining pattern were
chosen for further evaluation at higher magnification (xlOO). All
sections were evaluated by two of the authors (PR and GL) for
determination of the interobserver variability. Staining of
neoplastic epithelial and stromal components was evaluated sepa-
rately for the three antibodies. Two ofthe MMP-2-stained sections
and one of the MMP-9-stained sections were difficult to classify
and excluded from further analyses.
The following arbitrary scale of staining was used for each
antibody.
MMP-2
Epithelial staining intensity was classified as weak, moderate or
strong (Figure 1) and epithelial staining localization as focal
(< 50% cells) or diffuse (> 50% cells).
MMP-9
The number of positive macrophages infiltrating the tumour
stroma (Figure 2) was counted in five fields of vision at xlOO
magnification. The patients were divided into four groups (quar-
tiles) based on either the mean, minimum or maximum number of
MMP-9-positive macrophages in the five fields of vision.
Macrophages were identified by morphological criteria and by
immunostaining of a random subset of 33 out of 212 adjacent
sections with an anti-macrophage antibody, CD 68 (Dakopatts,
Glostrup, Denmark).
TIMP-2
Weak epithelial staining and positive interstitial stromal staining
were both classified as focal (<50%) ordiffuse (>50%). The base-
ment membrane staining (continuous or discontinuous) was, when
present, distributed focally (< 50%) or diffusely (> 50%) in the
sections. Subglandular staining enhancement was described as
present or absent. Various TIMP-2 staining patterns are shown in
Figure 3.
Statistical evaluation
The X2 test was used to test for differences in distribution between
groups. P-values of less than 0.05 were considered statistically
significant. Life table (cancerspecific) survival analysis was used to
examinethe effectofindividual variables on survival. Differences in
survival between groups weretestedfor statistical significance using
the log-rank test (Peto et al, 1977; Lawless, 1982).
RESULTS
The number of tumours showing various staining characteristics
obtained by the three antibodies is given in Table 1.
MMP-2
Positive cytoplasmic staining for MMP-2 was restricted to tumour
epithelium, with no staining of interstitial stroma or basement
membranes (Figure 1). The intensity and distribution ofthe MMP-2
staining did not correlate with Dukes' stage or survival time. There
was a tendency for poorly differentiated tumours to be MMP-2
negative more often than moderately and well-differentiated
tumours (X2 = 5.29, d.f. = 2, P < 0.08).
MMP-9
Tumour epithelium, basement membranes and interstitial stroma
were all negative for MMP-9. Macrophages in the interstitial stroma
and at the tumour invasive edge were positive (Figure 2). Dukes'
stage and survival timedidnotvary toanymajorextentwhenpatients
who were divided into four quartiles based on either the mean,
minimum or maximum number of tumour macrophages were
compared. Poorly differentiated tumours werecompared with moder-
ately and well-differentiated tumours, significantly correlated with a
higher number of MMP-9-positive macrophages when the mean or
maximum number was considered in the five fields of vision (%2 =
9.75, d.f. = 3, P < 0.05 andX2 = 9.04, d.f. = 3, P <0.05 respectively).
TIMP-2
Tumour epithelium, basement membranes and interstitial stroma
expressed positive staining for TIMP-2 (Figure 3).
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Figure 3 Sections from colorectal cancer illustrating (A) TIMP-2-positive basement membrane staining (arrows), (B) TIMP-2 positive interstitial stroma,
(C) TIMP-2 subglandular staining enhancement (arrows) and (D) TIMP-2-negative interstitial stroma
Tumour epithelium generally displayed a weaker staining than
the other tissue components and, furthermore, the staining was
weaker than that ofthe MMP-2 epithelium. The TIMP-2 epithelial
staining was not correlated with tumour differentiation, tumour
stage or survival time (data not shown).
The glandular basement membranes showed TIMP-2 positivity
(continuous or discontinuous) expressed either as focal or diffuse
stainings. There was a significantly higher number of tumours
expressing positive basement membrane staining compared with
those with negative basement membranes in Dukes' stages A and
B (%2 = 10.76, d.f. = 1, P < 0.01; Table 1), while no correlation
with tumour differentiation was found. In addition, patients with
tumours expressing TIMP-2 in the basement membranes had a
longer survival time than those who were negative (log-rank test
%2 = 3.899, P < 0.05; Figure 4A).
The interglandular tumour stroma was positive for TIMP-2 in
almost all ofthe tumours (nine tumours were negative). Tumours in
Dukes' stages A and B expressed diffuse stromal staining signifi-
cantly more often than the metastatic tumours in Dukes' stages C
and D, which more often showed focal staining (x2 = 6.35, d.f. = 1, P
< 0.05; Table 1). Moreover, there was a subglandular enhancement
of the stromal staining in 55 (27%) sections compared with the
overall stromal staining intensity. This enhancement was signifi-
cantly more frequent in Dukes' stages A and B compared with the
metastatic stages C and D (x2 = 4.13, d.f. = 1, P < 0.05). Patients
operated for tumours with diffuse stromal staining tended to have a
longer survival time than those operated for tumours with focal
stromal staining, but the difference was not statistically significant
(log-rank test X2 = 3.498, P < 0.07; Figure 4B). Similarly, patients
operated for tumours with subglandular stromal enhancement had
significantly longer survival time than those operated for tumours
without (log-rank testX2 = 5.653, P <0.05; Figure 4c); there were no
distribution differences according to tumour differentiation.
The above-observed survival differences, according to the
various TIMP-2 staining patterns, were found when the entire
material was analysed. When similar analyses were performed on
the subset oflocalized tumours, no significant survival differences
according to the TIMP-2 staining patterns were observed - TIMP-
2 staining of basement membranes: log-rank test X2 = 2.090, P =
0.1483; TIMP-2 stromal staining: log-rank test X2 = 1.767, P =
0.1837; and TIMP-2 subglandular stromal enhancement: log-rank
test X2 = 0.819, P = 0.3654.
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Table I Number of tumours showing various staining characteristics using
the anti-MMP-2, anti-MMP-9 and anti-TIMP-2 antibodies
Expression Antigen
MMP-2 MMP-9 TIMP-2
(n = 210) (n=211) (n = 212)
Epithelial staining intensity
Strong 44 0
Moderate 45 0
Weak 46 93
Negative 75 119
Epithelial staining localization
Diffuse (> 50%) 60
Focal (< 50%) 75
Negative 75
No. of positive macrophages
Mean
Quartile 1 5-13 54
Quartile 2 14-49 54
Quartile 3 50-87 52
Quartile 4 88-402 51
Minimum
Quartile 1 5-9 56
Quartile 2 10-37 51
Quartile 3 38-74 53
Quartile 4 75-322 51
Maximum
Quartile 1 5-16 54
Quartile 2 17-60 53
Quartile 3 61-104 54
Quartile 4 105-501 50
Basement membrane staining
Continuous 4
Discontinuous 57
Negative 151
Interstitial stromal staining
Diffuse 129
Focal 74
Negative 9
Subglandular staining enhancement
Present 55
Absent 157
MMP-2 and TIMP-2
Nothing further was gained with regard to tumour staging and/or
prognostic prediction when tumours expressing MMP-2-negative
epithelium and TIMP-2-positive basement membranes and
TIMP-2-positive homogenous interstitial stroma or subglandular
staining enhancement were compared with tumours expressing
diffuse MMP-2-positive epithelial stainings and TIMP-2-negative
stainings of the basement membranes and interstitial stroma (data
not shown).
Interobserver variability
MMP-2
In 14 out of210 (7%) sections the two observers disagreed on the
intensity and in 16 out of210 (8%) sections on the localization.
MMP-9
No differences were observed according to which tumours
belonged to each quartile ofthe macrophages.
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Figure 4 Life-table plots for the entire material with survival curves for
patients operated for tumours. (A) TIMP-2-positive (continuous or
discontinuous) basement membrane staining (-) and TIMP-2-negative
basement membrane staining (...). (B) Diffuse TIMP-2-positive interstitial
stromal staining (-) and focal TIMP-2-positive interstitial stromal staining
(...). (C) TIMP-2 subglandular staining enhancement present (-) and
TIMP-2 subglandular staining enhancement absent (...)
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In 41 out of 212 (19%) sections, there was disagreement as to
whether the epithelium was negative or positive with a focal distri-
bution as to whether the positive epithelium was focally or
diffusely distributed in the sections. In 19 out of 212 (9%), there
was a different opinion on whether there were focally positive
basement membranes or on whether all basement membranes were
stained negatively. Subglandular staining enhancement was evalu-
ated with less than 5% disagreement. Tumour stroma was classi-
fied differently according to focal or diffuse staining in 32 out of
212 (15%) sections.
All sections for which the two observers disagreed were
re-evaluated and, after discussion, there was total agreement on
the classification.
DISCUSSION
It is obvious that the positive ECM expression ofTIMP-2 is corre-
lated with localized tumours. TIMP-2-positive staining of base-
ment membranes and interstitial stroma, and the predominant
relations ofthese stainings to localized tumours, were reflected in
the survival analyses ofthe entire material. However, this correla-
tion was lost when patients operated for tumours with regional and
distant metastases were excluded. This finding indicates that the
observed survival differences for the entire material in the first
place can be attributed to differences in tumour staging.
The results on the distribution ofTIMP-2 stainings are similar to
those reported in earlier studies. The TIMP-2 positivity was most
prominent in the tumour stroma, a finding also reported by others
(Poulsom et al, 1992; Urbanski et al, 1993; Hoyhtya et al, 1994).
Studies on the closely related TIMP-1 have shown similar distribu-
tion, predominantly to the ECM of colorectal tumours (Hewitt et
al, 1991; Newell et al, 1994; Kossakowska et al, 1996), but we are
not aware of any studies exploring the relation between TIMP-1
expression and tumour staging and survival in colorectal cancer.
Wefound weakfocal or weak diffuse epithelial TIMP-2 staining in
as many as 93 (44%) out of the 212 tumours, while Hoyhtya et al
(1994) observed strong cytoplasmic staining in 22% of tumour
epithelium but, as the clinicopathological variables in these patient
materials are possibly not identical, no conclusions may be drawn.
We observed that negative epithelial MMP-2 expression tended
to correlate with apoor tumour differentiation, whereas Liabakk et
al (1996) showed that the MMP reactivity was not correlated to
tumour differentiation. Similar to the findings in that study, no
correlation with the survival time was observed. In contrast to
what has been reported previously (Levy et al, 1991; Hoyhtya et
al, 1994), the present data do not show that the number ofMMP-2-
positive tumour epithelial cells is correlated with the tumour stage.
This was also suggested in reports by Urbanski et al (1993) and
Liabakk et al (1996).
The MMP-2 staining was localized throughout the cytoplasm of
epithelial cells in the present study, in agreement with earlier
reports by Levy et al (1991) and Hoyhtya et al (1994). In one
report (Hoyhtya et al, 1994), in which a MMP-2 antibody recog-
nizing both the active and inactive forms of MMP-2 was used, all
35 investigated colonic cancers showed positive staining of
tumour epithelium without referring to tumour stage, while
approximately one-third of the total number of tumours stained
negatively in the present study.
We were not able to detect any stromal MMP-2 staining.
However, Tryggvason et al (1993) detected MMP-2-positive
fibroblasts near the invasive edge using immunohistochemistry,
and Poulsom et al (1992) observed that desmoplastic stromal cells
produced MMP-2 in greater quantities than tumour epithelium
using in situ hybridization. Pyke et al (1993) detected MMP-2
mRNA in adenocarcinomal stromal fibroblasts and fibroblast-like
cells but not in tumour epithelium. Furthermore, Newell et al
(1994) and Liabakk et al (1996) detected MMP-2 mRNA in the
stromal cells. Pyke et al (1993) has suggested 'that the discrepancy
between the immunohistochemical and mRNA expressions may
be caused due to a lack of direct relationship between mRNA
expression and the amount of protein present, e.g. because a high
expression in some cells may be only transient. The discrepancy
may also reflect a binding and/or internalization in the cancer cells
of enzyme produced by the fibroblasts, or it may be related to the
specificity of the anti-peptide antibodies which are used in the
immunohistochemical study'.
In the present study, a high number of MMP-9-positive
macrophages correlated with poor tumour differentiation. There
was no association between the number of MMP-9-positive
macrophages and the tumour stage or survival time - observations
that have also been noted by Liabakk et al (1996). This finding is
compatible with the suggestion that MMP-9-positive macrophages
are of advantage for the penetration of tumour cells into the inter-
stitial stroma. The MMP-9 staining was restricted to the tumour-
infiltrating macrophages and macrophages close to the invasive
edge. Similarly, Tryggvason et al (1993) made the observation that
the MMP-9 was expressed by macrophages near the edge using
immunohistochemistry. The same finding was made by Pyke et al
(1993) and Nielsen et al (1996), who studied the MMP-9 expres-
sion at the mRNA level. It has been speculated that macrophages
use MMP-9 for penetration ofthe ECM during migration in tissues
(Tryggvason et al, 1993).
Jessup et al (1994) has concluded that there is a basic TIMP-2
status in tissues that has to be overcome by increased MMP-2
production to promote invasiveness. In the present study, we
observed, however, that both the positive epithelial MMP-2
staining and the TIMP-2-positive basement membranes and inter-
stitial stromal staining were more often absent or weak in tumours
with poor differentiation, in contrast to the above-mentioned
hypothesis of tumour invasion. Furthermore, in the present study
tumours positive for MMP-2 and negative for TIMP-2 did not
have a poorer outcome than those with the inverse relation
between MMP-2 and TIMP-2, which also defies the hypothesis on
the metastatic level. Thus, the possible interactive processes
between the metalloproteinases and their inhibitor has not been
further elucidated. Hewitt et al (1991) and Emmert-Buck et al
(1994) also considered that it must be remembered that antibodies
may react with the proenzyme and not only the activated enzyme.
In the present study, the MMP-9 antibody reacts with both latent
and active MMP-9 and MMP-9-TIMP complexes; the TIMP-2
antibody reacts with free TIMP-2 and the MMP-TIMP-2
complex, while the MMP-2 antibody reacts with proMMP-2 as
well as with the proMMP-2-TIMP-2 complex.
TIMP-2 expression, which is possible to investigate in tumour
biopsies, may be of importance during the preoperative tumour
staging, when the most suitable treatment has to be selected for
each patient. However, neither of the studied TIMP-2 staining
variables could predict which of the potentially cured patients
would be cured by surgery and which patients would. have
micrometastases, indicating that the TIMP-2 expression is not a
valuable prognostic factor. TIMP-1 expression and its possible
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additional value to TIMP-2 analyses have to be further explored in
staging and prognostic prediction ofcolorectal cancer.
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